Effect Of Vitamin D Supplementation, Directly Or Via Breast Milk For Term Infants, On Serum 25 Hydroxyvitamin D And Related Biochemistry, And Propensity To Infection: A Randomised Placebo-controlled Trial
|Values||Baby elevated ALP (>450 7·5 µkat/l). Mother supplement: 2/50 Baby supplement: 0/46 Placebo: 8/50|
|Trial Design||Randomized trial|
|Trial Length||6+ Months|
|Number of Subjects||230|
In a randomized, double-blind, placebo-controlled trial, 230 mother-infant pairs were given 3000µg/month of vitamin D for the mother, or 10µg to the infant, or placebo for 9 months.
The primary outcome was the infant's vitamin D levels at 3.5 months and they were significantly higher in both vitamin D groups compared with placebo and not notably different than each other. The parathyroid hormone levels of the mothers were significantly lower in the group where the mothers received supplementation than the others, and the baby's parathyroid levels were significantly lower in both vitamin D groups than placebo, with no notable differences. Alkaline phosphatase for the infants was significantly lower in the vitamin D groups. The number of days the infants had respiratory or diarrhoeal infection was significantly lower in the vitamin D groups.
78 pairs didn't complete the trial and weren't included in the primary analysis.